GW4 Takes a 'One Health' Strategy to Combat Antimicrobial Resistance

ReachMD Healthcare Image


Photo: Pixabay

The World Health Organisation cites antimicrobial resistance (AMR) as one of the most significant risks facing the world. AMR threatens global health and development as it impacts on human, animal and plant health and also our environment, water safety and food security.

The GW4 AMR Alliance has been established to tackle this global challenge and become the UK's leading interdisciplinary 'One Health' AMR research consortium, recognized worldwide.

Today's launch event showcases GW4's cross-disciplinary AMR research collaborations and some of the One Health AMR projects and programs being undertaken by GW4 teams and their collaborators.

Antimicrobial resistance where bacterial, fungal, viral, and parasitic infections become resistant to existing antimicrobial drugs is an increasing global societal threat, as there is no matching increase in new antibiotics or new therapies to help treat patients' infections.

The COVID-19 pandemic has brought the 'pandemic' of AMR into sharper focus. Antimicrobial use, which drives the emergence of AMR, increased in many intensive care units around the world, as clinicians mitigated the development of secondary bacterial and fungal infections in acutely ill hospitalized patients. AMR is a slower moving, 'silent pandemic' but requires urgent action now to stop resistance expanding and find drugs to treat these infections.

The GW4 AMR Alliance builds on and enhances the GW4 universities' strong and diverse portfolio of AMR research. Its vision is to tackle AMR using a One Health approach and to be the partner of choice for future AMR research consortia funding to help mitigate the urgent threat of AMR.

Dr. Timothy Jinks, Head of the Drug-Resistant Infections Programme at the Wellcome Trust, who is delivering the keynote lecture, said: "Containing and controlling AMR requires collaborative, long-term, interdisciplinary and sustainable research taking a global One Health approach. It is great news that the GW4 AMR Alliance is launching to increase understanding, development, and implementation of effective interventions."

GW4's proven academic excellence in AMR research across disciplines and across institutions is demonstrated by a portfolio of AMR-relevant research funding in excess of £40m.

Dr. Joanna Jenkinson, GW4 Alliance Director, commented: "Our strategic initiative is in total accord with the G7 Health Ministers' recent communique (on 4 June) which outlined the need to act on the growing pandemic of AMR with 'clear leadership, bold science-based actions and a One Health approach, 'recognizing and understanding that the health of humans, animals, plants and their shared environment are inextricably interlinked'. The GW4 has fostered collaborative AMR projects at scale to achieve more than our institutions can individually. We are also proud to support our early career researchers (ECR) through our Crucible program on 'Interdisciplinary Approaches to AMR' and opportunities to apply for seed funding. We are delighted that one new ECR AMR community, further supported by our GW4 Generator Award funding scheme, is contributing a presentation at the launch today on their project to find new antibiotic leads."

AMR disproportionately affects low-and-middle income countries and the research being showcased today demonstrates our global reach with collaborative GW4 projects taking place in Thailand, China, Bangladesh, Argentina, India and here in the UK. GW4 researchers are exploring what drives the emergence of AMR in different settings e.g. the environment (particularly in aquatic systems from industrial and domestic waste), livestock farming, aquaculture, and healthcare.

Identifying the drivers of AMR will help to help modify them by informing policy and implementing interventions to mitigate this rising threat. In the UK alone, there was a 9% increase in deaths caused by drug-resistant infections between 2017 and 2018.

Chair of the GW4 AMR Alliance, Prof Eshwar Mahenthiralingam (Cardiff University), said: "This is a very exciting and timely consortium bringing the considerable AMR research strengths across the GW4 universities together to work as one cohesive unit to drive forward our understanding of, and to develop new interventions for containing and controlling AMR."

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free